Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To describe the development and progression of neuropathy and related findings among patients with type 1 diabetes who participated in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. RESEARCH DESIGN AND METHODS: The main diabetic peripheral neuropathy (DPN) outcome was assessed using clinical symptoms, signs, and nerve conduction study results during DCCT and repeated in EDIC year 13/14. Cardiovascular autonomic neuropathy (CAN) was assessed by R-R response to paced breathing, Valsalva ratio, and blood pressure response to standing during DCCT and in EDIC years 13/14 and 16/17. Additionally, symptoms reflecting neuropathic pain and autonomic function (including hypoglycemia awareness) were collected yearly in EDIC using standardized questionnaires; peripheral neuropathy was also assessed annually using the Michigan Neuropathy Screening Instrument. Assessments of genitourinary function were collected at EDIC year 10. RESULTS: Intensive therapy during the DCCT significantly reduced the risk of DPN and CAN at DCCT closeout (64% and 45%, respectively, P < 0.01). The prevalence and incidence of DPN and CAN remained significantly lower in the DCCT intensive therapy group compared with the DCCT conventional therapy group through EDIC year 13/14. CONCLUSIONS: The persistent effects of prior intensive therapy on neuropathy measures through 14 years of EDIC largely mirror those observed for other diabetes complications. DCCT/EDIC provides important information on the influence of glycemic control, and the clinical course of diabetic neuropathy, and, most important, on how to prevent neuropathy in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The diagnosis of DPN is principally a clinical one.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Diabetes Control and Complications Trial (DCCT) and its observational follow-up study, Epidemiology of Diabetes Interventions and Complications (EDIC), conclusively demonstrated that intensive glucose control applied early in the course of type 1 diabetes (T1D), significantly reduces the risk of developing CAN [2–4].”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Electrophysiological testing or referral to a neurologist is rarely needed for diagnosis, except in situations where the clinical features are atypical, the diagnosis is unclear, and a different etiology is suspected.547,554,565”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
The global burden of diabetic foot disease
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G., & Apelqvist, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67698-2 · Cited by 2,566 · cited 1×
“Painful symptoms are frequently refractory to treatment, and loss of protective sensation heightens the risk for foot ulceration and lowerextremity amputations (19,20).”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop‐Busui, R., Stevens, M., Kempler, P., Hilsted, J., Tesfaye, S., et al. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1239 · Cited by 957
Self-citationEffect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1895 · Cited by 578 · cited 1×
“Yet, CAN is an independent predictor of mortality (21,22), possibly by promoting life-threatening arrhythmias and sudden death in response to a variety of insults including drug side effects, hypoglycemia, hypokalemia, hypotension, or ischemia (23).”
Background
Cited by
Items 301–400 of 572
Statin therapy and neuropathy in type 1 diabetes: A cross‐sectional study
Pasha, R., Kamath, A., Linn, Z., Kalteniece, A., Bashir, B., Schofield, J. D., Malik, R. A., Azmi, S., Ferdousi, M., & Soran, H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16617 · Cited by 7
Yue, Y., Deng, M., Liao, S., Xiao, G., & Huang, Y. (2023) · Journal of Visualized Experiments · doi:10.3791/65421 · Cited by 7
Wang, J., Zhang, Y., Wu, Q., Bian, Z., Luo, N., Sun, J., Yu, B., & Fang, J. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302228 · Cited by 7
“However, previous meta-analyses have also reported that symptoms in DPN patients are less affected by blood glucose, indicating that glycemic management measures alone might not be adequate to stop DPN from developing or worsening [8].”
ResultDanjo, J., Sawada, H., Uchida, K., Danjo, S., & Nakamura, Y. (2017) · Journal of General and Family Medicine · doi:10.1002/jgf2.47 · Cited by 7
A diabeteses cardialis autonóm neuropathia diagnosztikája
Sztanek, F., Jebelovszki, É., Gaszner, B., Zrínyi, M., Páll, D., Kempler, P., & Harangi, M. (2019) · Orvosi Hetilap · doi:10.1556/650.2019.31491 · Cited by 7
“Klinikai szempontból a legjelentősebb és leggyakrabban vizsgált a cardialis autonóm neuropathia (CAN), melynek előfordulása még igen alacsony 1-es típusú diabetesben a diagnózis megállapításakor, viszont a DCCT/EDIC alvizsgálata alapján 20 éves betegségtartam után a prevalenciája 30% körüli [8].”
Abdissa, D., Sorsa, R., Gerbi, A., Hamba, N., & Banjaw, Z. (2021) · Heliyon · doi:10.1016/j.heliyon.2021.e08460 · Cited by 7
Pahuja, V., Punjot, P., Fernandes, G., & Chatterjee, N. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00735-0 · Cited by 7
Mizokami‐Stout, K., Li, Z., Foster, N. C., Ang, L. P., & Pop‐Busui, R. (2020) · Diabetes Care · doi:10.2337/dci20-0028 · Cited by 7
Self-citationMing, A., Clemens, V., Lorek, E., Wall, J., Alhajjar, A., Galazky, I., Baum, A.-K., Li, Y., Li, M., Stober, S., et al. (2024) · Journal of Medical Internet Research · doi:10.2196/52323 · Cited by 6
“The definition of PNP is based on the widely used diagnostic criteria (a combination of NSS, NDS, and monofilament testing) but implemented separately for each foot side [31].”
InfluentialXing, Y., Chai, X.-J., Liu, K., Cao, G., & Wei, G. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03815-7 · Cited by 6
“As for the association between insulin treatment and DN, the Diabetes Control and Complications Trial demonstrated intensive insulin therapy reduces nephropathy in type 1 diabetes (T1DM) [28, 29].”
Baldimtsi, E., Amezcua, S., Ulander, M., Hyllienmark, L., Olausson, H., Ludvigsson, J., & Wahlberg, J. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3825 · Cited by 7
Danjo, J., Danjo, S., Nakamura, Y., UCHIDA, K., & Sawada, H. (2016) · IEICE Transactions on Information and Systems · doi:10.1587/transinf.2015edp7354 · Cited by 6
Epigenetic Alterations Are Associated With Gastric Emptying Disturbances in Diabetes Mellitus
Narayanan, S. P., Lee, J., Bhagwate, A. V., Kuwelker, S., Yan, H., Ördög, T., & Bharucha, A. E. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000136 · Cited by 6
Rethinking Neuropathy in Type 1 Diabetes: Had We Lost Sight of What Matters Most?
Perkins, B. A. (2020) · Diabetes Care · doi:10.2337/dci19-0076 · Cited by 6
Wysocka‐Mincewicz, M., Baszyńska–Wilk, M., Mazur, M., Byczyńska, A., & Nowacka-Gotowiec, M. (2021) · Metabolites · doi:10.3390/metabo11110795 · Cited by 6
“Strict glycemic control is an undeniable factor for the prevention of DPN in T1D patients [29,30].”
BackgroundVieira, A. R. S. D. A., Porto, L. B., Romani, F. A. D. P., Carvalho, P. S., Pop‐Busui, R., & Pedrosa, H. C. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01036-7 · Cited by 6
Self-citationLaursen, J. C., Curovic, V. R., Kroonen, M. Y. A. M., Jongs, N., Zobel, E. H., Hansen, T. W., Frimodt‐Møller, M., Laverman, G. D., Kooy, A., Persson, F., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15180 · Cited by 6
“CAN is preventable to some extent: Intensive glucose control demonstrated a 45% risk reduction of CAN in persons with type 1 diabetes in the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC).(2) To our knowledge, however, no treatment is available when CAN i…”
BackgroundProfil Neuropati Perifer dan Korelasinya dengan Kadar Gula Darah Sewaktu di Panti Lansia Santa Anna
Sim, A. S., Wijaya, D. A., Nathaniel, F., Yogie, G. S., Firmansyah, Y., Sugiarto, H., Amadea, S., & Santoso, A. H. (2023) · Malahayati Nursing Journal · doi:10.33024/mnj.v5i9.11121 · Cited by 6
Stem Cells Reprogramming in Diabetes Mellitus and Diabetic Complications: Recent Advances
Madkor, H. R., El‐Aziz, M. K. A., El‐Maksoud, M. S. A., Ibrahim, I. M., & Ali, F. E. M. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998275428231210055650 · Cited by 6
Early detection of peripheral neuropathy in patients with diabetes mellitus type 2
Fadel, A. W., Nawar, A. E., Ahwal, L. E., Ghali, A. A., & Ragab, O. A. A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00782-9 · Cited by 6
“Maintaining optimal HbA1c levels is essential to prevent or delay the onset of diabetic complications such as neuropathy [13].”
BackgroundMaiti, R., Misra, D. S., & Ghosh, D. (2014) · American journal of phytomedicine and clinical therapeutics · Cited by 6
Type 1 Diabetes, Celiac Disease, and Neuropathy—A Nationwide Cohort Study
Thawani, S. P., Brannagan, T. H., Lebwohl, B., Mollazadegan, K., Green, P. H. R., & Ludvigsson, J. F. (2017) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000174 · Cited by 6
Thioctic Acid and Vitamin B Complex Improves Clinical Sings in Diabetic Peripheral Neuropathy
Rotaru, A., Albu, C. V., Tudoraşcu, D. R., Cătălin, B., Gheonea, M., Udriștoiu, I., & Iancău, M. (2019) · Revista de Chimie · doi:10.37358/rc.19.10.7607 · Cited by 6
Association between plasma apolipoprotein M and cardiac autonomic neuropathy in type 1 diabetes
Safi, M., Borup, A., Hansen, C. S., Rossing, P. R., Jensen, M. T., & Christoffersen, C. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109943 · Cited by 6
Management of Diabetes Mellitus
Jenkins, A. J., SCOTT, E. S., Fulcher, J., Kilov, G., & Januszewski, A. S. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_7 · Cited by 6
Yang, J., Zhao, D., Chen, Y., Ma, Y., Shi, X., Wang, X., Lv, Y., & Yuan, H. (2021) · Journal of Diabetes Investigation · doi:10.1111/jdi.13495 · Cited by 6
Pedrosa, H. C., Braver, J. D., Rolim, L. C., Schmid, H., Calsolari, M. R., & Odriozola, A. (2019) · Alad · doi:10.24875/alad.18000352 · Cited by 6
Braffett, B. H., El ghormli, L., Martin, C., White, N. H., Hirsch, I. B., Bantle, A., Carlson, A., Leschek, E., Gubitosi-Klug, R., Soliman, E. Z., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02856-9 · Cited by 5
“…Complications Trial (DCCT) and its observational follow-up study, Epi-demiology of Diabetes Interventions and Complications (EDIC), conclusively demonstrated that intensive glucose control applied early in the course of type 1 diabetes (T1D), significantly reduces the risk of developing CAN [2–4].”
Self-citationAraszkiewicz, A., Borys, S., Broncel, M., Budzynski, A. Z., Cyganek, K., Cypryk, K., CYRANKA, K. M., Czupryniak, L., Dąbrowski, M., Dzida, G. J., et al. (2026) · Current Topics in Diabetes · doi:10.5114/ctd/219306 · Cited by 5
Tanashyan, M. М., Антонова, К. В., & Раскуражев, А. А. (2017) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2017-17-72-80 · Cited by 5
Tentolouris, A., & Tentolouris, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-62263-3_27 · Cited by 5
Li, Y., Wang, Y., Cao, Y., Zhang, X., Dai, W., Zhao, Y., Zhang, L., & Han, X.-F. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s454531 · Cited by 5
Jiang, J.-J., Shen, H., Zhang, Y., Li, Y., Jing, Y., Chen, X., Wu, H., Xie, Y., & Liu, H. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1420510 · Cited by 5
Wasser, W. G., Gil, A., & Skorecki, K. L. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10214 · Cited by 5
Update 2014 zur diabetischen Neuropathie
Ziegler, D. (2014) · Der Diabetologe · doi:10.1007/s11428-014-1195-7 · Cited by 5
Picard, S., Hanaire, H. P., Reznik, Y., Benhamou, P., Fendri, S., Dufaitre, L., Leutenegger, É., & Guerci, B. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0002 · Cited by 5
Improved quality of diabetes control reduces complication costs in Bulgaria
Tachkov, K., Mitov, K., Mitkova, Z. E., Kamusheva, M., Dimitrova, M. J., Petkova, V. B., Savova, A., Doneva, M., Tcarukciev, D., Valov, V., et al. (2019) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2019.1604160 · Cited by 5
Medical and socio-demographic determinants of depressive disorders in diabetic patients
Florek-Łuszczki, M., Choina, P., Kostrzewa-Zabłocka, E., Panasiuk, L., & Dziemidok, P. (2020) · Annals of Agricultural and Environmental Medicine · doi:10.26444/aaem/118529 · Cited by 5
“It is estimated that the risk of occurrence of neuropathy increases 10 years after the occurrence of diabetes in patients with both type 1 and 2 diabetes, and concerns 40–50% of those afflicted with this disease [5, 6, 7, 8, 9].”
BackgroundHossain, M., Sarkar, M., Mahbub, I., & Islam, S. (2021) · Journal of Bio-Science · doi:10.3329/jbs.v29i0.54825 · Cited by 5
“Neuropathy is the most common of all complications of diabetes estimated around 60% (Martin et al. 2014).”
BackgroundPing, F., Dong, J., Zeng, F., & Tang, Z. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12584 · Cited by 5
Yang, Y., Liu, L., Wang, H. H., Lu, Y., Li, J., Liu, P., Hu, Z., & Yang, X. Q. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112847 · Cited by 4
“In patients with T1DM, optimal blood glucose management not only serves to prevent or delay the onset of DPN but also reduces the likelihood of diabetic autonomic neuropathy (Ang et al., 2014; Martin et al., 2014).”
A Multi-Marker Approach for Improved Glycemic Management in Diabetes Mellitus
Belle, J. T. L. (2017) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2017.04.00124 · Cited by 4
Patil, M. M., Dhruw, A., & Gupta, S. (2018) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20183120 · Cited by 4
Kamel, J. T., Loh, M., Cook, M. J., MacIsaac, R. J., & Roberts, L. J. (2019) · Muscle & Nerve · doi:10.1002/mus.26738 · Cited by 4
“ropathy is seen in the Epidemiology of Diabetes Interventions and Complications study at 14 years follow-up.(5) Hemoglobin A1c is a commonly used marker of longer term diabetes control.”
BackgroundShariff, E. A., & Qahtani, F. A. (2020) · Saudi Journal of Medicine · doi:10.36348/sjm.2020.v05i04.008 · Cited by 4
“Similar findings were reported by other studies [4, 21-23].”
ResultThe conundrum and enigma of painful and painless neuropathy
Røikjer, J., & Ejskjær, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-820669-0.00012-8 · Cited by 4
Britten‐Jones, A. C., Wu, M., Roberts, L. J., MacIsaac, R. J., Jiao, H., Craig, J. P., Chinnery, H. R., & Downie, L. E. (2024) · The Ocular Surface · doi:10.1016/j.jtos.2024.08.011 · Cited by 4
Gad, H., Elgassim, E., Mohamud, K., Al‐Naimi, N. S., Al-Sharshani, H., Mohammed, I., Al-Malaheem, M. A. O., Quadros, D. J., AlJalahma, A., Lamine, N., et al. (2025) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70026 · Cited by 4
Diabetes update: Your guide to the latest ADA standards.
Johnson, E. L., Warren, F., SKOLNIK, N., & Shubrook, J. H. (2016) · PubMed · Cited by 4
Glycemic Control Assessment in the Dialysis Patient: Is Glycated Albumin the Answer?
Molitch, M. E. (2017) · American Journal of Nephrology · doi:10.1159/000485844 · Cited by 4
DIABETIC CARDIOVASCULAR NEUROPATHY
Publisher, L., Serhiyenko, V., & Serhiyenko, A. A. (2018) · Logos Publisher eBooks · doi:10.18411/dia012018.49 · Cited by 4
Bhandari, R., Badyal, P., Khanna, G., & Kuhad, A. (2022) · Springer eBooks · doi:10.1007/978-981-16-9232-1_20 · Cited by 4
Acosta‐González, R. I., Hernández-Jiménez, A. Y., Ramírez-Quintanilla, L. Y., Torres-Rodríguez, H. F., Vargas-Muñoz, V. M., & Jiménez‐Andrade, J. M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00634-0 · Cited by 4
“Among these complications, diabetic periph - eral neuropathy emerges as a prevalent issue, impacting approximately 6% of patients with DM, with the prevalence escalating to 30% after 13–14 years of disease progression [5].”
Amoli, M. J., Kalantari, K. K., Niajalili, M., Daryabor, A., & Naimi, S. S. (2024) · Turkish Journal of Physical Medicine and Rehabilitation · doi:10.5606/tftrd.2024.13419 · Cited by 3
“[13] Tecar is one of the electromagnetic waves whose beneficial effects have been reported in the treatment of musculoskeletal injuries such as low back pain [14] and Achilles tendonitis.”
BackgroundZiori, M., Tentolouris, A., Eleftheriadou, I., Voudouri, A., Simati, S., Aissopou, E. K., Anastasiou, I. A., Mitsikostas, D. D., THEODOSSIADIS, P. G., & Tentolouris, N. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109290 · Cited by 3
Clinical Diagnosis of Diabetic Peripheral Neuropathy
Perkins, B. A., & Bril, V. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_5 · Cited by 3
Zhou, J., Mychaleckyj, J. C., Önengüt-Gümüşcü, S., Orchard, T. J., Costacou, T., & Miller, R. G. (2025) · Diabetologia · doi:10.1007/s00125-025-06427-1 · Cited by 3
“The DCCT/EDIC study clearly demonstrated the beneficial effects of intensive glycaemic management on reducing neuropathy risk [3].”
Hadid, S. A., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000940 · Cited by 3
Fu, B., Luo, N., Zeng, Y., Chen, Y., Wie, L., & Fang, J. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1434756 · Cited by 3
Jiang, T., Wang, D., Chai, R., Hu, Y., Zhū, L., Fang, F., Li, N., Wan, C., & Liu, F. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70042 · Cited by 3
“…or reflex abnormalities indicative of distal symmetrical poly-neuropathy) and abnormal nerve conduction tests (characterised by at least one abnormal nerve property—amplitude, latency, F‐wave or nerve conduction velocity—in two or more nerves, including the median, peroneal and sural nerves) [18].”
Wang, L., Guan, B., Li, G., Feng, L., Hui, S., & Xu, J. (2022) · Medicine · doi:10.1097/md.0000000000031467 · Cited by 3
“[23] Clinically, Western medicine methods for treating DPN mainly concern blood sugar control,[24] drug therapy, neurolysis,[25] and electrical nerve stimulation.”
Admoni, S. N. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-25082017-075846 · Cited by 3
A diabeteses cardiovascularis autonóm neuropathia klinikuma, diagnosztikája és terápiája
Kempler, P., & Körei, A. E. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33027 · Cited by 2
Solomos, Z., Pappa, E., & Tentolouris, N. (2025) · Journal of Migration and Health · doi:10.1016/j.jmh.2025.100345 · Cited by 2
“In the DDCT / EDIC study, the prevalence of DN in adults with type 1 DM was 6 % at baseline and increased to 30 % after 13 – 14 years of patient follow-up (Martin et al., 2014).”
SLOAN, G. P., Azmi, S., Eid, S., Ferdousi, M., Røikjer, J., Κender, Ζ., D’Onofrio, L., Karlafti, E., Callaghan, B. C., & Perkins, B. A. (2026) · Journal of the Peripheral Nervous System · doi:10.1111/jns.70124 · Cited by 2
“Long-term observational studies and large randomised trials, such as DCCT/EDIC, showed clear benefits of intensive glycaemic control in preventing or delaying DPN onset, but not reversal of established disease [58].”
Ghalichi, F., Molani‐Gol, R., Tejareh, F., & Payahoo, L. (2026) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-026-00609-x · Cited by 2
“Annually, a high burden of costs is imposed on healthcare systems due to the management of diabetes and its related complications [8, 9].”
The pivotal role of immunometabolism in diabetic neuropathy and its potential therapeutic strategies
Lin, R., Zhang, X., Yang, X. J., Tang, R., Bao, T., & Zhao, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1791057 · Cited by 2
Gunaid, A. A. (2018) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551417749217 · Cited by 2
Ivanov, D. D., & Ivanova, M. D. (2020) · KIDNEYS · doi:10.22141/2307-1257.9.3.2020.211461 · Cited by 2
An ayurvedic approach to the diagnosis and management of diabetic neuropathy
Parveen, R., & Baruah, H. (2019) · AYUHOM · doi:10.4103/ayuhom.ayuhom_3_21 · Cited by 2
Neuropathie diabétique : mise au point
Lopes, S. A., Fayolle, D., & Jornayvaz, F. R. (2022) · JMIG · doi:10.53738/revmed.2022.18.784.1106 · Cited by 2
Precision Medicine for Diabetic Neuropathy
Davalos, L., Stino, A. M., Selvarajah, D., Sakowski, S. A., Tesfaye, S. H., & Feldman, E. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_8 · Cited by 2
TYPE 2 DIABETES MELLITUS AND ITS VASCULAR COMPLICATIONS
Valodara, A., & Johar, K. (2022) · Towards Excellence · doi:10.37867/te140218 · Cited by 2
Diabetic neuropathy: Current issues in diagnosis and prevention
Spallone, V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00016-6 · Cited by 2
From receptor to response: dissecting the TLR4 pathway in diabetic neuropathy
Hernandez-Reyes, M., & Oo, T. T. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01774-2 · Cited by 2
“…of DNP has been extensively researched, but there are currently few effective treatment options, leaving patients with sensory deficits, chronic pain, and a higher risk of serious complications like amputations and foot ulcers (Feldman et al. 2019; Martin et al. 2014; Quiroz-Aldave et al. 2023).”
Treatment Options for Diabetic Neuropathy: Insights from the Romanian Neuropathy Guidelines
Nica, A. E., Parliteanu, O. A., Claudia, S., Dobjanschi, C. G., Rusu, E., & Radulian, G. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009813 · Cited by 3
Morgan, N. (2018) · UND Scholarly Commons (University of North Dakota) · Cited by 2
Zinman, B. (2014) · Diabetes Care · doi:10.2337/dc14-1601 · Cited by 2
A Methodology to Compare Insulin Dosing Recommendations in Real-Life Settings
Groat, D., Grando, A., Thompson, B., Neto, P. C. M., Soni, H., Boyle, M. E., Bailey, M., & Cook, C. B. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817704444 · Cited by 2
Bordier, L. V. L., & Herisse, J.-H. C. G. L. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000618 · Cited by 2
“Thus diabetes mellitus is the leading cause of blindness, end-stage renal disease and non-traumatic limb amputations [3-5].”
BackgroundWeight-Bearing Exercise and Foot Health in Native Americans
Cuaderes, E., DeShea, L., & Lamb, W. L. (2014) · Care management journals · doi:10.1891/1521-0987.15.4.184 · Cited by 2
Saul Genuth, MD: Clinical Researcher and Leader in Developing Modern Diabetes Treatment
Jacobson, A. M., & Nathan, D. M. (2015) · Diabetes Care · doi:10.2337/dc14-1396 · Cited by 2
Absent monofilament sensation in a type 2 diabetic feet
Cheong, J. L. Y., Αλεξιάδου, Κ., & Devendra, S. (2017) · London Journal of Primary Care · doi:10.1080/17571472.2017.1370813 · Cited by 2
Diabetes and the Nervous System
Vinik, A. I., CASELLINI, C. M., & Neuman, S. (2018) · Endocrinology · doi:10.1007/978-3-319-27316-7_10-1 · Cited by 2
Diagnosis and Management of Diabetic Autonomic Neuropathy
Kim, C. H. (2018) · Journal of Korean Diabetes · doi:10.4093/jkd.2018.19.3.160 · Cited by 2
Classical Therapies Versus Combined Therapies in Diabetic Neuropathy.
Rotaru, A., Târtea, E. A., & Iancău, M. (2020) · PubMed Central · doi:10.12865/chsj.46.02.04 · Cited by 2
Interaction of Parenting Style of Mothers and Paediatric Diabetes Management
Žilinskienė, J., Šumskas, L., Antinienė, D., & Jonynienė, J. (2021) · Baltic Journal of Sport and Health Sciences · doi:10.33607/bjshs.v1i120.1049 · Cited by 2
Cardiovascular Autonomic Neuropathy
Ang, L. P., & Pop‐Busui, R. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-15613-7_12 · Cited by 2
Self-citationTurčinović, K., Cigrovski, V., Bilić-Ćurćić, I., Mrzljak, A., Kuna, L., Klobučar, S., & Berković, M. C. (2023) · Acta Clinica Croatica · doi:10.20471/acc.2023.62.02.11 · Cited by 2
“Moreover, it has been reported that increased glucose variability, especially with overcoming the hypoglycemic stress, was associated with numbness in measures of heart rate variability in T1DM patients 31,32 .”
BackgroundStirban, O. A. (2022) · Diabetes aktuell · doi:10.1055/a-1876-1528 · Cited by 1
Comparison of efficacy of carbamazepine and duloxetiene for the treatment of diabetic neuropathy.
Tariq, A., Aslam, M. A., Ishtiaque, A., Azeem, G. M., Tariq, N., Shahid, F., & Ahsan, M. (2024) · The Professional Medical Journal · doi:10.29309/tpmj/2024.31.06.7964 · Cited by 1
Santos, R. D. F., Campos, T. D. L., & Pereira, L. M. D. O. (2024) · Revista Contemporânea · doi:10.56083/rcv4n6-158 · Cited by 1
Sztanek, F., Pető, A., Tóth, L. I., Lőrincz, H., Molnár, Á., Lukács, M., Menyhárt, A., Kempler, P., Paragh, G., Harangi, M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165780 · Cited by 1
“The Diabetes Control and Complications Trial showed that approximately 20% of people with type 1 diabetes (T1D) develop diabetic sensorimotor polyneuropathy (DSPN) within 20 years of disease onset [4].”
Retinopathy, Neuropathy, and Foot Care
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch19 · Cited by 1
Xu, X., Huang, S. D., Wang, F., Guo, L., Liao, S., Yang, M., & Wang, Z. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1746503 · Cited by 1
Complicações Neurológicas da Diabetes Mellitus
Borges, C., Costa, A., Guimarães, P., Pires, V., & Mendes, M. (2026) · Sinapse · doi:10.46531/sinapse/ar/132/2026 · Cited by 1
Dardari, D. (2026) · Diabetes · doi:10.2337/db26-0064 · Cited by 1
Yao, N., & Zhang, K. (2026) · Journal of Clinical Medicine Research · doi:10.14740/jocmr6642 · Cited by 1
“Relevant studies have verified that standardized intensive glycemic control combined with comprehensive multi-risk intervention can reduce DPN incidence by nearly 50% [14].”
Chakravarti, R., Bankar, P. R., Chigilipalli, J., Roy, D., Bhattacharya, B., Pradhan, A. K., Singh, R., Arya, M., Kundu, A., & Ghosh, D. (2026) · Vascular Pharmacology · doi:10.1016/j.vph.2026.107685 · Cited by 1
Diabetik polinöropatik hastalarda memantinin ağrı üzerine etkinliği
Gökçe, Ş. F., Çiğdem, B., Akyüz, A., Bolayır, E., & Topaktas, S. A. (2014) · Cumhuriyet Tıp Dergisi/Cumhuriyet Üniversitesi Tıp Fakültesi dergisi · doi:10.7197/cmj.v36i4.5000071418 · Cited by 1
Metadata
- Authors
- Martin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group
- Affiliations
- University of Michigan (US)
- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, MI
- Corresponding author
- Martin, Catherine L.
- ORCID
- Martin, Catherine L.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 31-38
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3868000
- OpenAlex
- W2115038969
- Cited by
- 499
- References
- 30
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 45 · 2023: 38 · 2022: 40 · 2021: 57 · 2020: 50 · 2019: 41 · 2018: 45 · 2017: 28 · 2016: 34 · 2015: 42 · 2014: 23 · 2013: 4
- FWCI
- 27.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Sanofi
- BD
- Roche Diabetes Care
- National Institutes of Health (UL1TR000041, UL1TR000114, 5u01dk094157-13, UL1TR001449)
- Abbott Diabetes Care
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK094176, U01-DK094157, P30DK020572)
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- diabetic peripheral neuropathy, cardiac autonomic neuropathy, type 1 diabetes, tight glycemic control, neuropathy progression, neuropathic pain, hypoglycemia awareness, genitourinary function, Michigan Neuropathy Screening Instrument, DCCT/EDIC, neuropathy prevention
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 1, Diabetic Neuropathies, Dose-Response Relationship, Drug, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Neural Conduction, Peripheral Nervous System Diseases, Risk Factors, Incidence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.